biostudies-literatureOliveira BBFundação para a Ciência e a TecnologiaUniversidade Nova de Lisboa2849-2863https://www.ebi.ac.uk/biostudies/studies/S-EPMC10185647biostudies-literatureUnknown415(14)The success of personalized medicine depends on the discovery of biomarkers that allow oncologists to identify patients that will benefit from a particular targeted drug. Molecular tests are mostly performed using tumor samples, which may not be representative of the tumor's temporal and spatial heterogeneity. Liquid biopsies, and particularly the analysis of circulating tumor DNA, are emerging as an interesting means for diagnosis, prognosis, and predictive biomarker discovery. In this study, the amplification refractory mutation system (ARMS) coupled with high-resolution melting analysis (HRMA) was developed for detecting two of the most relevant KRAS mutations in codon 12. After optimization with commercial cancer cell lines, KRAS mutation screening was validated in tumor and plasma samAnalytical and bioanalytical chemistryCombining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples.PMC10185647LA/P/0140/2020UIDB/04378/2020UIDP/04378/20202020.07660.BDCosta BCravo MVeigas BMaio RBaptista PVOliveira BBFernandes ARPereira LPAlbuquerque CFaias SMorao BfalseCombining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples.The success of personalized medicine depends on the discovery of biomarkers that allow oncologists to identify patients that will benefit from a particular targeted drug. Molecular tests are mostly performed using tumor samples, which may not be representative of the tumor's temporal and spatial heterogeneity. Liquid biopsies, and particularly the analysis of circulating tumor DNA, are emerging as an interesting means for diagnosis, prognosis, and predictive biomarker discovery. In this study, the amplification refractory mutation system (ARMS) coupled with high-resolution melting analysis (HRMA) was developed for detecting two of the most relevant KRAS mutations in codon 12. After optimization with commercial cancer cell lines, KRAS mutation screening was validated in tumor and plasma sam2023-01-01T00:00:00Z2023 Jun2025-04-05T09:10:18.432Z2025-04-05T09:10:18.432ZS-EPMC101856473709730410.1007/s00216-023-04696-6